| 货号 | 21482-1mg |
| 描述 | Bentamapimod is an orally bioavailable inhibitor of Jun kinases (JNKs), with IC50 values for JNK1, JNK2, and JNK3 of 80, 90, and 230 nM, respectively.1,2 It is selective for JNKs over a panel of 25 related kinases.1 Bentamapimod induces regression of endometriotic lesions without suppressing estrogen action in animal models of endometriosis.3,4 It blocks proliferation and induces apoptosis of T cells in vitro and inhibits cancer stem cell survival, self-renewal, and tumor-initiating capacity in vitro and in mice.2,5 |
| 别名 | AS-602801; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Halazy, S. Designing heterocyclic selective kinase inhibitors: From concept to new drug candidates. ARKIVOC ICHC-20(7), 496-508 (2006). 2.Ferrandi, C.,Richard, F.,Tavano, P., et al. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult. Scler. 17(1), 46-56 (2011). 3.Hussein, M.,Chair, D.C.,Kyama, C.M., et al. c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: An assessor-blind placebo-controlled randomized study. Fertil. Steril. 105(3), 518-824 (2016). 4.Palmer, S.S.,Altan, M.,Denis, D., et al. Bentamapimod (JNK Inhibitor AS602801) induces regression of endometriotic lesions in animal models. Reprod. Sci. 23(1), 11-23 (2016). 5.Okada, M.,Kuramoto, K.,Takeda, H., et al. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget 7(19), 27021-27032 (2016). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 457.5 |
| 分子式 | C25H23N5O2S |
| CAS号 | 848344-36-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |